Novel anti-Nectin-4 antibodies and antibody drug conjugates
By developing monoclonal antibodies that specifically bind discontinuous epitopes on Nectin-4, the shortcomings of existing antibodies in anti-cancer activity and cell selectivity were solved, efficient recognition and attack on tumor cells were achieved, and toxicity to normal cells was reduced.
Patent Information
- Application Number
- CN202380055454.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-07-22
- Filing Date
- 2023-07-20
- Publication Date
- 2025-04-04
AI Technical Summary
When existing anti-Nectin-4 antibodies bind Nectin-4, it is difficult to effectively improve anti-cancer activity, and have high affinity and internalization activity for normal cells, resulting in related toxicity.
A monoclonal antibody or antigen-binding fragment of its antigen-binding fragment was developed that specifically binds to discontinuous epitopes on Nectin-4, and the critical amino acid epitope was identified by deep mutation scanning (DMS), and the variable region structure of the antibody was designed and optimized to improve affinity and selectivity for tumor cells.
The novel antibody showed improved anti-cancer activity compared with known anti-Nectin-4 antibodies, and significantly improved binding affinity and internalization activity on tumor cells, while reducing the impact on normal cells, achieving a higher therapeutic index.